References

Estimating Risk for Death from Coronavirus Disease, China, January-February 2020

10.3201/eid2606.200233 · 2020 · External reference

Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020

10.2807/1560-7917.es.2020.25.31.2001383 · 2020 · External reference

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

10.1056/nejmoa2115481 · 2022 · External reference

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2

10.1056/nejmoa2118946 · 2022 · External reference

Omicron BA.2.86 cross-neutralising activity in community sera from the UK

10.1016/s0140-6736(23)02397-8 · 2023 · External reference

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

10.1093/cid/ciac443 · 2023 · External reference

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

10.1056/nejmoa2116846 · 2022 · External reference

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

10.1056/nejmoa2116044 · 2022 · External reference

Unresolved reference

External reference

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

10.1038/s41467-024-45641-0 · 2024 · External reference

Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis

2021 · External reference

Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic

10.1002/jmv.28231 · 2023 · External reference

Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19

10.1016/s1473-3099(21)00251-6 · 2021 · External reference

Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers

10.7554/elife.71131 · 2021 · External reference

Impact of removing the healthcare mask mandate on hospital-acquired COVID-19 rates

10.1016/j.jhin.2023.12.004 · 2024 · External reference

Impact of supplementary air filtration on aerosols and particulate matter in a UK hospital ward: a case study

10.1016/j.jhin.2023.02.006 · 2023 · External reference

Efficacy of air cleaning units for preventing SARS-CoV-2 and other hospital-acquired infections on medicine for older people wards: a quasi-experimental controlled before-and-after study

10.1016/j.jhin.2024.09.017 · 2024 · External reference

Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission

10.1016/j.epidem.2022.100567 · 2022 · External reference

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19

10.1038/s41591-021-01310-z · 2021 · External reference

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

10.1038/s41586-020-2180-5 · 2020 · External reference

Association of IFNAR1 and IFNAR2 with COVID-19 severity

10.1016/s2666-5247(23)00095-2 · 2023 · External reference

The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review

10.3390/microorganisms9081692 · 2021 · External reference

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

10.1038/s41586-022-05594-0 · 2023 · External reference

Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis

10.1111/joim.13630 · 2023 · External reference

Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting

10.1002/jmv.29418 · 2024 · External reference

Effect of Ursodeoxycholic Acid for Sars-Cov-2 Prevention in Hematological Malignancies: An Observational Real-World Study

10.1182/blood-2023-182862 · 2023 · External reference

Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease

10.3389/fcimb.2023.1178590 · 2023 · External reference

A Retrospective Study in Patients With Varying Prescription Coverage With Ursodeoxycholic Acid and Association With Incidence of COVID-19 Diagnosis in Primary Care

2023 · External reference

Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study

10.1093/qjmed/hcad254 · 2023 · External reference

Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort

10.3389/fcimb.2024.1324019 · 2024 · External reference

Assessing respiratory epidemic potential in French hospitals through collection of close contact data (April-June 2020)

10.1038/s41598-023-50228-8 · 2024 · External reference

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group

10.1056/nejm199405123301903 · 1994 · External reference

Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens

10.1073/pnas.96.9.5095 · 1999 · External reference

SARS-CoV-2 within-host diversity and transmission

10.1126/science.abg0821 · 2021 · External reference

Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis

10.1001/jamanetworkopen.2021.22240 · 2021 · External reference

Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model

2022 · External reference

Impact of interventions to reduce nosocomial transmission of SARS-CoV-2 in English NHS Trusts: a computational modelling study

10.1186/s12879-024-09330-z · 2024 · External reference

Real-time nowcasting and forecasting of COVID-19 dynamics in England: the first wave

10.1098/rstb.2020.0279 · 2021 · External reference

Characterising within-hospitalSARS-CoV-2 transmission events using epidemiological and viral genomic data across two pandemic waves

10.1038/s41467-022-28291-y · 2022 · External reference